Cerebrolysin
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
Browse-only — not on the protocol builder's curated shortlist, so the builder won't recommend it.
What is it?
Cerebrolysin is a neurotrophic peptide preparation — and the “preparation” word matters, because unlike most entries in this wiki it isn’t one defined molecule. Per peptidelist, it is “a mixture of peptides and amino acids derived from pig brain tissue, researched extensively for neurotrophic and neuroprotective effects, particularly in cognitive recovery”. The manufacturer, EVER Neuro Pharma (Austria), produces it by enzymatic breakdown of purified porcine brain protein into a standardized blend of low-molecular-weight peptides (<10 kDa) and free amino acids designed to mimic the body’s own neurotrophic factors [0035; peptidelist].
That porcine-brain origin is also its defining practical feature: it’s administered by intravenous or intramuscular infusion in a clinical setting — not the at-home subcutaneous injection model of most research peptides. This is a drug with a 40-year prescribing history in much of the world, not a gray-market biohacking compound, even though in the US it sits in research-only status.
What does it do in my body?
Per peptidelist, Cerebrolysin “contains neurotrophic factors that may support neuronal survival, synaptic plasticity, and neurogenesis”. The mechanistic claim is that its peptide fraction acts like the brain’s endogenous neurotrophic signaling — the same family of “keep neurons alive and growing” signals that Semax and Selank upregulate indirectly via BDNF/NGF. Three proposed channels [0035; peptidelist]:
- Neuronal survival / neuroprotection — protecting neurons from ischemic and excitotoxic death, the rationale for its use in the acute window after a stroke.
- Synaptic plasticity — supporting the formation and remodeling of synaptic connections, the basis for the cognitive-recovery and dementia indications.
- Neurogenesis — supporting the generation of new neurons.
The honest caveat: because Cerebrolysin is a mixture rather than a single molecule, its mechanism is characterized at the level of “neurotrophic-factor-mimetic effects” rather than a clean single-receptor story. That’s a real difference from the rest of this wiki’s cognitive peptides, and it’s part of why Western reviewers grade the evidence cautiously even though the clinical-use history is long.
How can it help me?
Cerebrolysin is the rare peptide in this wiki with Phase 3 human data and decades of real clinical use — and also a genuinely mixed Western evidence picture we report honestly. It’s not a single peptide: it’s a standardized mixture of low-molecular-weight peptides and free amino acids derived from purified porcine (pig) brain tissue, manufactured by EVER Neuro Pharma in Austria. For 40+ years it has been a mainstay of European and Asian clinical neurology — prescribed by IV/IM infusion for stroke recovery, vascular dementia, and Alzheimer’s. The Western verdict is more cautious: real Phase 3 trials exist, but Cochrane rates the evidence “very low quality,” and there’s a specific hemorrhagic-safety signal in one stroke combination we surface up front rather than burying. Both things are true at once — long-standing established clinical use AND a real Western evidence-quality caveat — and an honest encyclopedia holds both.
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
The clinical-trial AE profile is generally mild at standard infusion dosing, with the specific signals noted above [peptidelist; 0035]:
- Infusion-related effects — the most common practical issue with IV/IM administration; managed by infusion-rate control in clinical settings.
- Allergy / hypersensitivity — because Cerebrolysin is a porcine-brain-derived biological mixture, allergic/hypersensitivity reactions are a recognized concern and part of why 0035 set the safety light to yellow (“IV admin + allergy + the SAE signal”).
- The non-fatal serious-AE signal in the acute-stroke Cochrane pool, and the hemorrhagic-transformation considerations in the alteplase-combination setting, detailed above.
Contraindications in standard clinical use include hypersensitivity to the product and (per labeling in approving countries) certain epileptic and severe-renal contexts.
Regulatory status: Cerebrolysin is approved and marketed across much of Europe, Asia, Russia, and Latin America, where it has a 40-year prescribing history for stroke, dementia, and TBI. In the United States it is NOT FDA-approved and is sold/handled as a research compound; peptidelist lists its US availability as “mixed” (some compounding-pharmacy and research-supplier access) and its formal status as research-only. WADA status is not a primary concern for this neurology compound. Factual, no editorializing: established prescription drug abroad, unapproved research compound in the US.
Typical dosing
Educational context only — talk to a licensed medical provider before any protocol. What follows describes the doses and schedules most commonly reported in the research and by practitioners, shared so you can have an informed conversation. These compounds are sold for research use only, are not FDA-approved drugs, and this is not medical advice.
Cerebrolysin is not a self-inject SubQ peptide — the established route is IV or IM infusion in a clinical setting, which is part of why it sits apart from the rest of this wiki’s at-home cognitive peptides. The clinical protocols documented in the countries where it’s approved (broadly, from the EVER Neuro Pharma labeling and the trial designs above) run as daily IV infusions over a 10–20 day course, repeated as cycles — the CARS and Alvarez trial structures reflect this multi-week course model rather than a continuous-dosing model [peptidelist; trial designs]. Specific dose-per-infusion and concentration vary by indication and are set clinically.
Because the established use is infusion-based and physician-administered in approving jurisdictions, there isn’t a “community insulin-syringe protocol” to report the way there is for self-inject peptides like BPC-157 or Semax. The honest statement is: the documented protocol is the clinical IV/IM course, not a DIY SubQ regimen.
What should I avoid combining — and what's synergistic?
Cerebrolysin doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.
Where do people source this?
OHM does not sell or handle any compound. Research-use-only material is sold by third-party vendors; our vetting notes and disclosures are on the Where to buy page. If you'd rather have a physician in the loop, see the telehealth option. Whatever the route, the supply chain is the real risk: only consider vendors that publish batch-level third-party Certificates of Analysis.
Cerebrolysin is the rare peptide in this wiki with Phase 3 human data and decades of real clinical use — and also a genuinely mixed Western evidence picture we report honestly. It’s not a single peptide: it’s a standardized mixture of low-molecular-weight peptides and free amino acids derived from purified porcine (pig) brain tissue, manufactured by EVER Neuro Pharma in Austria. For 40+ years it has been a mainstay of European and Asian clinical neurology — prescribed by IV/IM infusion for stroke recovery, vascular dementia, and Alzheimer’s. The Western verdict is more cautious: real Phase 3 trials exist, but Cochrane rates the evidence “very low quality,” and there’s a specific hemorrhagic-safety signal in one stroke combination we surface up front rather than burying. Both things are true at once — long-standing established clinical use AND a real Western evidence-quality caveat — and an honest encyclopedia holds both.
| What it is | Standardized peptide + free-amino-acid mixture from purified porcine brain tissue (EVER Neuro Pharma) |
| Class | Neurotrophic / neuroprotective peptide preparation |
| Mechanism | Mimics endogenous neurotrophic factors → neuronal survival, synaptic plasticity, neurogenesis |
| Route | IV or IM infusion (not a self-inject SubQ peptide) — the established clinical route |
| Primary clinical uses | Acute ischemic stroke recovery; vascular dementia; Alzheimer’s disease; TBI (European/Asian practice) |
| Evidence tier | **** — 30 studies / 29 human / 4 RCTs / Phase 3 reached; Cochrane grades it “very low quality” |
| Key safety signal | Hemorrhagic-transformation + non-fatal serious-AE signals in some stroke readouts (see below) |
| Regulatory | Approved/marketed across Europe, Asia, Russia, Latin America; NOT FDA-approved in the US (research-only there) |
What it is
Cerebrolysin is a neurotrophic peptide preparation — and the “preparation” word matters, because unlike most entries in this wiki it isn’t one defined molecule. Per peptidelist, it is “a mixture of peptides and amino acids derived from pig brain tissue, researched extensively for neurotrophic and neuroprotective effects, particularly in cognitive recovery”. The manufacturer, EVER Neuro Pharma (Austria), produces it by enzymatic breakdown of purified porcine brain protein into a standardized blend of low-molecular-weight peptides (<10 kDa) and free amino acids designed to mimic the body’s own neurotrophic factors [0035; peptidelist].
That porcine-brain origin is also its defining practical feature: it’s administered by intravenous or intramuscular infusion in a clinical setting — not the at-home subcutaneous injection model of most research peptides. This is a drug with a 40-year prescribing history in much of the world, not a gray-market biohacking compound, even though in the US it sits in research-only status.
How it works
Per peptidelist, Cerebrolysin “contains neurotrophic factors that may support neuronal survival, synaptic plasticity, and neurogenesis”. The mechanistic claim is that its peptide fraction acts like the brain’s endogenous neurotrophic signaling — the same family of “keep neurons alive and growing” signals that Semax and Selank upregulate indirectly via BDNF/NGF. Three proposed channels [0035; peptidelist]:
- Neuronal survival / neuroprotection — protecting neurons from ischemic and excitotoxic death, the rationale for its use in the acute window after a stroke.
- Synaptic plasticity — supporting the formation and remodeling of synaptic connections, the basis for the cognitive-recovery and dementia indications.
- Neurogenesis — supporting the generation of new neurons.
The honest caveat: because Cerebrolysin is a mixture rather than a single molecule, its mechanism is characterized at the level of “neurotrophic-factor-mimetic effects” rather than a clean single-receptor story. That’s a real difference from the rest of this wiki’s cognitive peptides, and it’s part of why Western reviewers grade the evidence cautiously even though the clinical-use history is long.
What the research shows
This is the unusual part: Cerebrolysin has more human data than almost any peptide in this wiki, and yet the Western quality verdict is mixed. Both facts deserve full weight.
The scale of the human record. Peptidelist grades it Strong: 30 studies cited, 19 human trials, Phase 3 reached. Its own evidence summary states the body comprises 29 human studies including 4 RCTs. By the raw count of human trials, this is a heavily-studied compound — the opposite of the animal-only profile common to bleeding-edge peptides.
What the trials actually found [all per KB doctrine on third-party citations]:
| Study | Year | Type / n | Finding |
|---|---|---|---|
| Muresanu DF et al. — CARS trial, Stroke ( 26564102) | 2016 | , 90-day | Cerebrolysin significantly improved upper-extremity motor function at day 90 post-stroke vs. placebo |
| Alvarez XA et al. — Eur J Neurol ( 20500802) | 2011 | , n=133, 12 wk | At all three dosages, improved global clinical function and cognition in moderate-to-moderately-severe Alzheimer’s |
| Khasanova DR, Kalinin MN — CEREHETIS pilot ( 37682097) | 2023 | , n=341 | With alteplase, reduced symptomatic hemorrhagic transformation — but no functional benefit at 90 days |
| Kalinin MN, Khasanova DR — CEREHETIS post-hoc ( 40123141) | 2025 | , n=238 | Reduced hemorrhagic-transformation risk; enabled earlier anticoagulation resumption |
So on the positive side: a placebo-controlled Phase 3-grade stroke trial (CARS) showing a real motor-recovery signal, and a double-blind Alzheimer’s RCT showing cognitive and global-function improvement. That’s a stronger positive human signal than most peptides in this KB can claim.
The Cochrane caveat: stated honestly. The Cochrane reviews of Cerebrolysin for acute ischemic stroke are the central Western quality verdict, and they are not flattering [all]:
- Ziganshina LE et al. 2023 Cochrane Database Syst Rev ( 37818733, n=1773): Cerebrolysin shows no benefit on mortality in acute ischemic stroke, with a potential increase in non-fatal serious adverse events.
- Ziganshina LE et al. 2020 ( 32662068, n=1601) and 2017 ( 28430363, n=1501): same conclusion — little or no clinical benefit for acute ischemic stroke, with a potential increase in non-fatal serious adverse events.
Peptidelist’s own integrated summary captures the split precisely: “Among 30 studies (29 human, 4 RCTs), cerebrolysin showed mixed efficacy: it reduced symptomatic hemorrhagic transformation when combined with alteplase in acute stroke but provided no functional benefit at 90 days, and while it improved cognition and global function in vascular dementia, the evidence quality was rated very low; additionally, cerebrolysin demonstrated no mortality benefit in acute ischemic stroke and raised concerns for increased non-fatal serious adverse events”.
The honest synthesis. Two readings coexist, and OHM reports both:
- The established-clinical-use reading: Cerebrolysin has a 40-year European/Asian prescribing record, a positive Phase 3 stroke motor-recovery trial (CARS), and a positive Alzheimer’s RCT (Alvarez). For vascular dementia and stroke rehabilitation it is genuinely a standard-of-care option across much of the world.
- The Western evidence-quality reading: Cochrane rates the acute-stroke evidence “very low quality,” finds no mortality benefit, and flags a non-fatal serious-AE signal. Where the trials are positive (motor function, dementia cognition), the methodological grade is weak by Western RCT standards.
Neither erases the other. 0035 landed it at Tier B (not A) precisely because of this split — “mixed efficacy + Cochrane quality grade + serious-AE concern… The Ph3 data exists but it isn’t a clean A”.
The hemorrhagic-SAE signal — surfaced, not buried
The one safety item that deserves its own section, because it’s specific and it’s real:
In the CEREHETIS trials, Cerebrolysin was given combined with alteplase (the clot-busting thrombolytic) in acute stroke. The headline finding was actually protective — it reduced symptomatic hemorrhagic transformation (bleeding into the infarcted brain tissue, a feared complication of thrombolysis): but it produced no functional benefit at 90 days in that readout [peptidelist; 0035, PMID 37682097]. Separately, the Cochrane reviews flag a potential increase in non-fatal serious adverse events in acute ischemic stroke generally, and network meta-analyses rated other neuroprotective agents (NBP, edaravone, edaravone dexborneol) as safer/more effective for acute stroke outcomes [peptidelist, PMIDs 37818733, 39575393, 39834702].
The honest read: the hemorrhagic-transformation data is mixed in direction (reduced bleeding in the alteplase combo, but a general non-fatal-SAE signal across the Cochrane pool) and concentrated in the acute-stroke-plus-thrombolytic setting — a hospital-managed scenario, not the elective-cognitive-enhancement use case. But it’s a documented signal, it’s why 0035 set the safety light to yellow, and an encyclopedia that aspires to be the credible source names it rather than reciting only the positive Alzheimer’s and motor-recovery results.
Real-world protocol
The information here is educational only. Cerebrolysin is administered by IV/IM infusion and is not FDA-approved in the US. This is not medical advice; the established protocols below are administered clinically in the countries where the drug is approved.
Cerebrolysin is not a self-inject SubQ peptide — the established route is IV or IM infusion in a clinical setting, which is part of why it sits apart from the rest of this wiki’s at-home cognitive peptides. The clinical protocols documented in the countries where it’s approved (broadly, from the EVER Neuro Pharma labeling and the trial designs above) run as daily IV infusions over a 10–20 day course, repeated as cycles — the CARS and Alvarez trial structures reflect this multi-week course model rather than a continuous-dosing model [peptidelist; trial designs]. Specific dose-per-infusion and concentration vary by indication and are set clinically.
Because the established use is infusion-based and physician-administered in approving jurisdictions, there isn’t a “community insulin-syringe protocol” to report the way there is for self-inject peptides like BPC-157 or Semax. The honest statement is: the documented protocol is the clinical IV/IM course, not a DIY SubQ regimen.
Side effects & management
The clinical-trial AE profile is generally mild at standard infusion dosing, with the specific signals noted above [peptidelist; 0035]:
- Infusion-related effects — the most common practical issue with IV/IM administration; managed by infusion-rate control in clinical settings.
- Allergy / hypersensitivity — because Cerebrolysin is a porcine-brain-derived biological mixture, allergic/hypersensitivity reactions are a recognized concern and part of why 0035 set the safety light to yellow (“IV admin + allergy + the SAE signal”).
- The non-fatal serious-AE signal in the acute-stroke Cochrane pool, and the hemorrhagic-transformation considerations in the alteplase-combination setting, detailed above.
Contraindications in standard clinical use include hypersensitivity to the product and (per labeling in approving countries) certain epileptic and severe-renal contexts.
Regulatory status
Cerebrolysin is approved and marketed across much of Europe, Asia, Russia, and Latin America, where it has a 40-year prescribing history for stroke, dementia, and TBI. In the United States it is NOT FDA-approved and is sold/handled as a research compound; peptidelist lists its US availability as “mixed” (some compounding-pharmacy and research-supplier access) and its formal status as research-only. WADA status is not a primary concern for this neurology compound. Factual, no editorializing: established prescription drug abroad, unapproved research compound in the US.
Technical & analytical reference (chemistry & QC)
Identity verified against reference sources (2026-06-21). Cerebrolysin is a mixture, not a single molecule, so single-formula/MW/sequence rows do not apply. Analytical-method detail below is compiled from a third-party technical reference (PeptideBiologix) and tagged where the underlying figure is uncited.
| Field | Value |
|---|---|
| Molecular formula | Peptide complex (mixture) — no single formula |
| Average MW | Variable; specification is ≥80% of peptide content <10 kDa (BBB-permissive fraction) |
| CAS | 12656-61-0 |
| Composition | ~80% low-MW peptides + ~20% free amino acids; “porcine brain-derived neurotrophic peptide complex (FPF-1070)”; mass-spec studies identify ~638 unique peptides |
| Concentration / formulation | 215.2 mg peptide concentrate per mL; aqueous, preservative-free; pH adjusted ~7.0-7.4 with NaOH |
| HPLC identity | RP-HPLC (C18, 0.1% TFA, 5-60% acetonitrile over 60 min, UV 214 nm) “fingerprint” for batch identity |
| MW-distribution QC | SEC-MALS requires ≥80% of peptide content <10 kDa, minimal high-MW aggregates |
| Neurotrophic-factor QC | BDNF/NGF/GDNF/CNTF quantified by sandwich ELISA (pg/mL detection); PC12 neurite-outgrowth + neuronal-survival bioassays for functional activity |
| Storage / stability | Sealed ampoules at controlled room temp 15-25°C, light-protected, do not freeze; 3-5 yr shelf life; diluted (saline/Ringer’s/5% dextrose) must infuse within 15-60 min; single-use, no preservative |
Primary-literature citation leads (PeptideBiologix; confirm before citing): Gevaert 2016 Drug Test Anal 8(1):67-74 (PMID 26017115, peptide profiling); Alvarez 2011 Eur J Neurol 18(1):59-68 (PMID 20482598 — note this is the analytical reference’s; the article body’s Alvarez citation already lists PMID 20500802, confirm which is correct); Wei 2023 Neurocrit Care 38(3):688-699 (PMID 36759493, TBI meta-analysis); Strilciuc 2012 Drugs Today 48 Suppl A:117-129 (PMID 22514795, safety review).
Sources
- — thepeptidelist.com profile: porcine-brain peptide mixture (EVER Neuro Pharma), 30 studies / 29 human / 4 RCTs / Phase 3, the integrated mixed-efficacy evidence summary, named RCT + Cochrane PMIDs (all), mixed US availability / research-only status.
- (lines 78–89) — Tier B / Safety Yellow / grading; the “why B not A” (mixed efficacy + Cochrane quality + SAE concern) and “why yellow” (IV admin + allergy + SAE signal) rationale; the OHM funcmed-lean editorial note (“long-standing European/Asian clinical-practice peptide… capture both sides honestly”); the open-VERIFY note on whether to upgrade from B/yellow (line 692).
- Cerebrolysin named anchors (all): Muresanu CARS 2016 26564102; Alvarez 2011 20500802; Khasanova CEREHETIS 2023 37682097; Kalinin CEREHETIS post-hoc 2025 40123141; Ziganshina Cochrane 2023 37818733 / 2020 32662068 / 2017 28430363.
Related: Semax · Selank · the Khavinson cognitive peptides (Pinealon, Cortagen) · Glutathione · BPC-157.
Sources & references
- — thepeptidelist.com profile: porcine-brain peptide mixture (EVER Neuro Pharma), 30 studies / 29 human / 4 RCTs / Phase 3, the integrated mixed-efficacy evidence summary, named RCT + Cochrane PMIDs (all), mixed US availability / research-only status.
- (lines 78–89) — Tier B / Safety Yellow / grading; the “why B not A” (mixed efficacy + Cochrane quality + SAE concern) and “why yellow” (IV admin + allergy + SAE signal) rationale; the OHM funcmed-lean editorial note (“long-standing European/Asian clinical-practice peptide… capture both sides honestly”); the open-VERIFY note on whether to upgrade from B/yellow (line 692).
- Cerebrolysin named anchors (all): Muresanu CARS 2016 26564102; Alvarez 2011 20500802; Khasanova CEREHETIS 2023 37682097; Kalinin CEREHETIS post-hoc 2025 40123141; Ziganshina Cochrane 2023 37818733 / 2020 32662068 / 2017 28430363.
Related: Semax · Selank · the Khavinson cognitive peptides (Pinealon, Cortagen) · Glutathione · BPC-157.